Safeland Spółka z Ograniczoną Odpowiedzialnością (KRS 0000680100, NIP 5472178908) is a Polish company, headquartered in Katowice, Śląskie voivodeship. SAFELAND operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since May 25, 2017. SAFELAND's most recently reported net revenue was 365.9 K PLN for 2022.
Negative equity
Negative equity in 2 of 3 available reporting years.
Arrears identified
The company has registered enforcement arrears.
Business profile - Safeland
Identity
- Name
- Safeland Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- May 25, 2017
- Registry status as of
- June 25, 2026
- Latest entry
- June 25, 2026
- Founding act
- 25.05.2017 R.
Articles of association history (2)
- May 25, 2017: 25.05.2017 R.
- March 12, 2021: 3.12.2021 R., AKT NOTARIALNY, REP A NR 4262/2021, NOTARIUSZ AGATA NIEŁACNA-SZOPA, KANCELARIA NOTARIALNA W KATOWICACH - ZMIENIONO §3,§4 I §6
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
Address and contact
- Address
- UL. OPOLSKA, 15, 40-084, KATOWICE, POLSKA
- Voivodeship
- ŚLĄSKIE
- District
- KATOWICE
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-29719-68866-UUSIJ-31
Risk and payment profile - Safeland
Credibility rating
77.5 / 100
Good credibility
Insolvency risk
Very low
Low threat
Closure risk
1
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
2
2/9 yrs
Board changes
1
1/9 yrs
PKD changes
2
2/9 yrs
Name changes
0
0/9 yrs
Data from 9 years of registry activity.
Credibility history
Payment reliability score from 2020–2022
Current: B (78/100)
Trend: improving (+31.9 pts/year)
High payment credibility - the company's financial condition is good and the risk of cooperating with it is low.
Trade credit limit history
Standard limit from 2020–2022
Current: 57.2 K PLN
Safe: 19.7 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Safeland
Founded
May 25, 2017
9 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
KATOWICE
ŚLĄSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
5.0 K PLN
100 shares total
Shareholders
4
shareholders
Board
1 person
Filed years
3 years
2020–2022 · profitable: 1/3
Registry entries
19
latest: June 25, 2026
Risk signals
Revenue
365.9 K PLN
2022
Net profit
61.0 K PLN
2022
Assets
91.0 K PLN
2022
Equity
56.3 K PLN
2022
EBITDA
67.1 K PLN
2022
Valuation
321.8 K PLN
High confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Safeland.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
